Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Trial Profile

Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bivalirudin (Primary) ; Heparin
  • Indications Myocardial infarction; Stroke; Thrombosis; Venous thromboembolism
  • Focus Adverse reactions
  • Acronyms VALIDATE-SWEDEHEART
  • Most Recent Events

    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
    • 01 Jul 2018 Results (data cutoff: 2008 to 2014) published in the American Heart Journal
    • 15 Nov 2017 Results of substudy of VALIDATE-SWEDEHEART trial presented at the 90th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top